title: Sclerotherapy with use of doxycycline after percutaneous drainage of postoperative lymphoceles.
abstract: OBJECTIVE
  To assess the use of doxycycline as a sclerosing agent after percutaneous drainage of postoperative lymphoceles.
  
  
  METHODS
  Symptomatic postoperative lymphoceles (n = 21) in 18 patients were treated by percutaneous tube drainage for an average of 10.8 days. Sclerosis was performed when the patient became asymptomatic, drainage had slowed to less than 30 mL/d and follow-up imaging (CT or US) showed either near complete or total resolution of the lymphocele. Doxycycline (500 mg) combined with 1% lidocaine (5 mL) was instilled into the cavity with use of a syringe after any remaining lymphocele fluid was removed through the tube. When possible, patients were instructed to perform a series of maneuvers for the next hour to distribute the sclerosing agent evenly throughout the cavity. After 1 hour, the sclerosing agent was aspirated from the cavity and the drainage tube was removed. Three patients with four lymphoceles underwent sclerotherapy immediately after percutaneous insertion of a drainage tube and aspiration of the lymphocele. No patients underwent previous sclerosis with any agent.
  
  
  RESULTS
  Successful treatment of postoperative lymphoceles was achieved in 17 of 18 patients. Primary success was achieved in 17 of 21 lymphoceles treated. There were four lymphocele recurrences in three patients. Three of the four recurrences were successfully treated by means of repeated drainage and sclerotherapy. One recurrent lymphocele persisted after re-treatment with 1 g of doxycycline. This patient underwent successful surgical repair. There were no complications related to doxycycline sclerosis. The mean duration of drainage for initial and recurrent lymphoceles was 10.8 days (range, 0-30 days).
  
  
  CONCLUSIONS
  Sclerotherapy with use of doxycycline after percutaneous drainage is an easy, safe, inexpensive, and effective means of treating postoperative lymphoceles.
authors.affiliation: Endovascular & Interventional Associates, Inc., East Greenwich, Rhode Island 02818, USA. mcaliendo.ei@home.com
authors.forename: M V
authors.initials: MV
authors.lastname: Caliendo
authors.forename: D E
authors.initials: DE
authors.lastname: Lee
authors.forename: R
authors.initials: R
authors.lastname: Queiroz
authors.forename: D L
authors.initials: DL
authors.lastname: Waldman
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use*; D004322:Drainage / Q000379:methods*; D005260:Female; D006801:Humans; D008210:Lymphocele / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000628:therapy; D012597:Sclerosing Solutions / Q000008:administration & dosage; D015911:Sclerotherapy / Q000379:methods*
chemical_list: D000900:Anti-Bacterial Agents; D012597:Sclerosing Solutions; D004318:Doxycycline